SCK CEN, legally known as Studiecentrum voor Kernenergie / Centre d'Etude de l'Energie Nucléaire, is the Belgian Nuclear Research Centre founded in 1952 and headquartered in Mol, Belgium. Operating as a foundation of public utility under the Belgian Federal Ministry of Energy, it employs over 900 staff and maintains an annual budget of approximately €180 million.
The centre conducts research in nuclear science and technology, with key focus areas including nuclear safety, radiation protection, radioactive waste management, advanced nuclear systems, nuclear materials science, and medical radioisotopes. It operates several research reactors, notably BR2—a high-flux materials testing reactor that supplies over 25% of the world's molybdenum-99—and BR1 for irradiation and training.
SCK CEN supports industrial applications through services like material testing, dosimetry, and isotope production, contributing to nuclear medicine, decommissioning, and sustainable energy solutions. Major projects include MYRRHA (accelerator-driven research reactor), RECUMO (radioactive residue decontamination), and NURA (next-generation radiopharmaceuticals for cancer therapy).
Also known as Belgian Nuclear Research Centre, SCK•CEN, Studiecentrum voor Kernenergie, and Centre d'Etude de l'Energie Nucléaire.
Consortium to build facility boosting production of a cancer radioisotope; scope includes HVAC, sanitation and technical gases. Construction started; equipment integration planned late 2026.
